We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Fusion Antibodies Plc | LSE:FAB | London | Ordinary Share | GB00BDQZGK16 | ORD 4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -1.47% | 3.35 | 3.30 | 3.40 | 3.40 | 3.35 | 3.40 | 1,029,509 | 09:00:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.9M | -2.6M | -0.0437 | -0.77 | 1.99M |
From May 2021 to May 2024
By Joe Hoppe
Fusion Antibodies PLC said Monday that its pretax loss widened for the first half of fiscal 2022 despite increased revenue, and it expects its full-year revenue to meet expectations.
The preclinical antibody discovery company posted a pretax loss for the six months ended Sept. 30 of 651,000 pounds ($861,664) compared with a loss of GBP572,000 for the same period a year earlier.
Revenue rose to GBP2.4 million from GBP1.9 million for the year-prior period, the company said.
Fusion said the positive first half, and in particular the securing of two major contracts and its remaining pipeline, give it confidence full-year revenue will meet expectations. However, the coronavirus pandemic and status of Brexit negotiations--particularly those related to Northern Ireland--continue to provide significant uncertainty. The company didn't provide any full-year guidance figures.
"We are delighted to report a strong all-round performance for the first half of the year with good revenue growth, major new contracts, collaboration agreements and increased investment into our research programs," Chief Executive Richard Jones said.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
December 06, 2021 03:12 ET (08:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Fusion Antibodies Chart |
1 Month Fusion Antibodies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
